AddedRisk Factors
Our reliance on third parties presents additional risks. Our partners and vendors are increasingly incorporating AI into their offerings, which may not meet existing or rapidly evolving regulatory or industry standards, including with respect to privacy and data security. We have limited control over our partners’ and vendors’ data practices, security measures, and review processes, and unfavorable changes in accuracy or functionality could harm our operations.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedRisk Factors
We also use AI technologies licensed from third parties, and our ability to continue to use such technologies at scale may be dependent on access to specific third-party software and infrastructure. We cannot control the availability or pricing of such third-party AI technologies, and we may be unable to negotiate favorable economic terms with the applicable providers. If any such third-party AI technologies become incompatible with our operations or unavailable for use, our business may be adversely affected. Additionally, the use of sensitive or proprietary data in AI workflows, by either us or third parties, may increase risks relating to privacy, cybersecurity, confidentiality, and intellectual property, including inadvertent disclosures or use of data for model training in ways that conflict with our legal obligations or customer expectations.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedRisk Factors
The legal and regulatory landscape for AI is rapidly evolving and may impose new requirements related to transparency, validation, documentation, governance, and data usage. Complying with these obligations could increase costs, slow product development and deployment, and create additional liability if we or our vendors fail to meet them. AI also presents emerging ethical and social issues and if our use of AI becomes controversial, we may experience competitive or reputational harm. If we are unable to effectively manage the risks associated with our increasing usage of AI technologies, including ensuring the accuracy and reliability of outputs, safeguarding data, and maintaining robust governance, our business, financial condition, and results of operations could be adversely affected.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
On or after March 16, 2013, under the Leahy-Smith America Invents Act, or the America Invents Act, enacted in September 16, 2011, the United States transitioned to a first inventor to file system in which, assuming Assuming that other requirements for patentability are met, in the United States, the first inventor to file a patent application will be is entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
Among other things, pursuant to the FDCA and its implementing regulations, the FDA regulates the research, design, testing, manufacturing, safety, labeling, storage, recordkeeping, premarket clearance or approval, marketing and promotion and sales and distribution of medical devices in the United States to ensure that medical devices distributed domestically are safe and effective for their intended uses.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
Because the interpretation and application of laws, regulations, standards and other obligations relating to data privacy and security are still uncertain, it is possible that these laws, regulations, standards and other obligations may be interpreted and applied in a manner that is inconsistent with our data processing practices and policies or the features of our products.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
Data Privacy Framework, which serves as a replacement to the Privacy Shield. Shield, it is uncertain whether this framework will be overturned in court like the previous two EU-U.S. bilateral cross-border transfer frameworks.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
In 2020, November 2025, we sold $1,150,000,000 $402.5 million aggregate principal amount of 0% convertible senior notes due 2027, 2033, or the 2033 Notes (together with the 2027 Notes. Notes and 2031 Notes, the Notes).
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
To date, we have financed our operations principally from the sale of stock or convertible securities, and revenue from precision oncology testing, and development services and other. generation of our revenue.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
For the years ended December 31, 2024, 2023 2025, 2024 and 2022, 2023, we incurred net losses of $416.3 million, $436.4 million, $479.4 million and $654.6 $479.4 million, respectively.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
Competitors within the broader genomics profiling space based on tissue include laboratory companies such as Bio-Reference Laboratories, Inc., Laboratory Corporation of America and Quest Diagnostics, Inc., and most if not all of the competitors within the liquid biopsy space for therapy selection, that sell molecular diagnostic tests for cancer to physicians and have or may develop tests that compete with our tests.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
Furthermore, biopharmaceutical companies may decline to do business with us or decrease or discontinue their use of our tests due to their broad strategic collaboration with any of our competitors.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
In addition, some countries have stricter consumer notice and/or consent requirements relating to personal data collection, use or sharing, more stringent requirements relating to organizations’ privacy programs and provide stronger individual rights.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
Even though the FDA has since resumed standard inspection operations of domestic facilities where feasible, the FDA has continued to monitor and implement changes to its inspectional activities to ensure the safety of its employees and those of the firms it regulates as it adapts to the evolving COVID-19 pandemic, regulates, and any resurgence of the virus or emergence of new variants may lead to further inspectional delays.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
For example, the California Consumer Privacy Act, or CCPA went into effect on January 1, 2020, and CCPA, creates certain data privacy rights for California residents.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
This will require requires us to be cognizant of the time from invention to filing of a patent application.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
The option counterparties are financial institutions, and we will be are subject to the risk that any or all of them may default under the 2027 Note Hedge transactions.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
We derive our revenue from four major sources, including oncology, biopharma and data, screening, and licensing and other.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
Biopharma and data. Biopharma and data revenue includes amounts derived from the delivery of our tests for biopharmaceutical customers, previously presented as precision oncology revenue from tests for biopharmaceutical customers. Biopharma and data revenue also includes amounts derived from the performance of our service agreements with biopharmaceutical customers, previously presented as a component of development services and other revenue, primarily comprised of companion diagnostic development and regulatory approval, monitoring and maintenance, GuardantINFORM data services and GuardantConnect referral services.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
Screening. Screening revenue, previously included in other revenue, includes amounts derived from the delivery of our Shield screening tests. In August 2024, following the FDA approval, our Shield screening test met the coverage requirements by Medicare, and we submit claims to Medicare for reimbursement for our Shield screening tests performed for qualifying patients. We also submit claims to private payers for reimbursement for qualifying patients covered under Medicare Advantage program. In addition, in March 2025, our Shield screening test received coverage for patients receiving community care authorized by the U.S. Department of VA, as an in-network benefit, with no copay for average-risk individuals who are age 45 or older. Following Medicare coverage for our Shield screening test in August 2024, the VA network coverage is the first for individuals between the ages of 45 and 64.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
Licensing and other. We also derive revenue from licensing our technologies, previously included in other revenue.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
Oncology revenue was previously presented as precision oncology revenue from tests for clinical customers. Oncology revenue includes amounts derived from the delivery of our oncology tests for clinical customers, including hospitals, cancer centers, research institutions and patients, and oncology tests delivered by labs operated by our strategic partners.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
Biopharma and data revenue includes amounts derived from the delivery of our tests for biopharmaceutical customers, previously presented as precision oncology revenue from tests for biopharmaceutical customers. Biopharma and data revenue also includes amounts derived from the performance of our service agreements with
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
biopharmaceutical customers, previously presented as a component of development services and other revenue, primarily comprised of companion diagnostic development and regulatory approval, monitoring and maintenance, GuardantINFORM data services and GuardantConnect referral services.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
Screening revenue, previously included in other revenue, includes amounts derived from the delivery of our Shield screening tests. As is the case with our Oncology revenue, we recognize our Screening revenue at the time the results of the tests are reported. Due to consistencies with our Oncology revenue, we apply the concepts of variable consideration under the portfolio approach to our Screening revenue in a manner consistent with that of our Oncology revenue, described above.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
We also derive revenue from licensing our technologies, previously included in other revenue. We recognize licensing and other revenue based on the nature and terms of the technology licensing arrangements.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RemovedMD&A
principally from the sale of our stock, convertible senior notes, and revenue from our precision oncology testing and development services and other. In May 2023, we completed a follow-on underwritten public offering, in which we issued and sold 14,375,000 shares of our common stock at a price of $28.00 per share, and received net proceeds of $381.4 million after deducting underwriting discounts and commissions and other offering costs of $21.1 million. In December 2023, we completed a registered direct offering with an investment management firm, in which we issued and sold 3,387,446 shares of our common stock at a price of $26.77 per share, and received net proceeds of $90.6 million. As of December 31, 2024, we had cash, cash equivalents, restricted cash and marketable debt securities of approximately $944.2 million.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
We derive our revenue from two sources: (i) precision oncology testing, and (ii) development services and other.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
Development services and other. Development services revenue primarily represents services that we provide to biopharmaceutical companies, large medical institutions and international laboratory partners. We collaborate with biopharmaceutical companies in the development and clinical studies of new drugs. As part of these collaborations, we provide services related to regulatory filings to support companion diagnostic device submissions for our test panels. Under these arrangements, we generate revenue from progression of our collaboration efforts, as well as from provision of on-going support. In addition to companion diagnostic development and regulatory approval services, we also provide other development services, including clinical study setup, monitoring and maintenance, testing development and support, GuardantConnect and GuardantINFORM. Other revenue includes amounts derived from licensing our technologies, kit fulfillment and delivery of our Shield screening tests.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
In August 2024, we entered into an Open Market Sales Agreement, or the Sales Agreement, with Jefferies LLC, or the Agent, with respect to an at-the-market offering program under which we may offer and sell, from time to time at our sole discretion, shares of our common stock, having aggregate gross proceeds of up to $400.0 million through the Agent, subject to the terms and conditions of the Sales Agreement. During the year ended December 31, 2024, no shares of our common stock were sold under the Sales Agreement.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
Year Ended December 31, 2024 2023 (in thousands) Net cash used in operating activities $ (239,858) $ (324,975) Net cash (used in) provided by investing activities (261,308) 840,250 Net cash (used in) provided by financing activities (996) 477,375
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
We perform development services for our biopharmaceutical customers utilizing our precision oncology information platform. Development services typically represent a single performance obligation as we perform a significant integration service, such as analytical validation and regulatory submissions. The individual promises are not separately identifiable from other promises in the contracts and, therefore, are not distinct. However, under certain contracts, a biopharmaceutical customer may engage us for multiple distinct development services which are both capable of being distinct and separately identifiable from other promises in the contracts and, therefore, distinct performance obligations.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
We recognize companion diagnostic development and regulatory approval services revenue over the period in which biopharmaceutical research and development services are provided. Specifically, we recognize revenue using an input method to measure progress, utilizing costs incurred to-date relative to total expected costs as its measure of progress. We assess the changes to the total expected cost estimates as well as any incremental fees negotiated resulting from changes to the scope of the original contract in determining the revenue recognition at each reporting period. For development of new products or services under these arrangements, costs incurred before technological feasibility is reached are included as research and development expenses in our consolidated statements of operations, while costs incurred thereafter are recorded as cost of development services and other.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
We also recognize revenue from other development services, in addition to companion diagnostic development and regulatory approval services noted above, such as clinical study setup, monitoring and maintenance, testing development and support, GuardantConnect, and GuardantINFORM. These revenues are generally recognized over time based on an input method to measure progress in the period when the associated services have been performed.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
In addition, we license our digital sequencing technologies to our domestic customers and international laboratory partners. For the licensed technology, we are compensated through royalty-based payments, non-refundable upfront payments, guaranteed minimum payments, and/or sample milestone payments. Depending on the nature of the technology licensing arrangements, and considering factors including but not limited to enforceable right to payment and payment terms, and if an asset with alternative use is created, these technology licensing revenues are recognized in the period when royalty-bearing sales occur, when the technology transfer is complete, or over the technology transfer period. Other revenue also includes kit fulfillment, which is recognized when such products are delivered. In addition, other revenue includes amounts derived from delivery of our Shield screening tests.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
marketplace. In assessing whether a promised service is distinct within the context of the contract, we consider whether we provide a significant integration of the services, whether the services significantly modify or customize one another, or whether the services are highly interdependent or interrelated.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RewordedMD&A
Cash provided by financing activities during the year ended December 31, 2023 2025 was $477.4 $671.1 million, which was primarily attributable to proceeds from issuance of convertible senior notes of $402.5 million, proceeds from equity offerings offering of $493.1 $257.1 million, proceeds from treasury stock reissuance upon equity offering of $87.9 million, proceeds from exercise of stock options of $19.2 million, and proceeds from issuances of common stock under our employee stock purchase plan of $10.2 $13.6 million; partially offset by repurchase of treasury stock of $45.0 million, employee taxes paid related to net share settlement of restricted stock units of $30.5 million, payment of debt issuance costs of $24.6 million, and payment of equity offering costs of $21.1 million, and employee taxes paid related to settlement of restricted stock units of $11.2 $17.7 million.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
Cost of precision oncology testing(1) 260,581 205,528 Cost of development services and other(1) 29,218 21,524 revenue(1) 349,007 289,799 Research and development expense(1) 364,191 347,753 367,194 Sales and marketing expense(1) 494,661 364,935 295,227 General and administrative expense(1) 211,410 180,123 155,800 Other operating expense — 83,400 Total costs and operating expenses 1,419,269 1,182,610 1,128,673 Loss from operations (437,248) (443,594) (564,725) Interest income 34,095 53,691 35,365 Interest expense (3,897) (2,581) (2,578) Other income (expense), net (10,490) (42,605) 53,174 Loss before (benefit from) provision for income taxes (417,540) (435,089) (478,764) Provision (Benefit from) provision for income taxes (1,263) 1,284 685 Net loss $ (416,277) $ (436,373) $ (479,449)
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
This increase was primarily due to an increase of $19.2 $15.9 million in stock-based compensation, including $4.1 an increase of $13.9 million related to the PSUs discussed in the Results of operation section above; information technology infrastructure costs, and an increase of $12.4 $4.0 million in other personnel outside service costs; partially offset by a decrease of $7.5 million in severance costs related to a workforce reduction in the first quarter of 2023, and a decrease of $3.1 $5.6 million in legal expenses.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
Other income (expense), net was a $42.6 $10.5 million expense for the year ended December 31, 2024, 2025, primarily attributable to $44.4 an impairment of $18.6 million of net unrealized and realized losses recorded for our marketable non-marketable equity security investment investments, partially offset by a gain on extinguishment of convertible notes of $13.7 million related to the convertible notes exchange transaction completed in Lunit, Inc. during the period. February 2025.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
This increase was related to commercial team expansion and marketing activities to support existing products and both the Shield product launch, launch and existing products growth, primarily resulting in an increase of $34.1 $77.0 million in other personnel costs; costs, an increase of $14.9 $35.1 million in marketing activity related costs; costs, an increase of $11.7 $8.2 million in stock-based compensation, including $6.5 an increase of $4.8 million related to the PSUs discussed in the Result of operations section above; office and administrative costs, and an increase of $10.5 $4.7 million in information technology infrastructure costs.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
Development services Licensing and other revenue increased to $51.1 was $13.5 million for the year ended December 31, 2024, from $49.7 compared to $23.7 million for the year ended December 31, 2023, an increase a decrease of $1.4 $10.2 million, or 3%. 43%, primarily due to a decrease of $7.2 million associated with our partnership agreements and a reduction of $3.2 million in royalty revenue.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
In September 2024, we signed a partnership agreement with the Fondazione Policlinico Universitario Agostino Gemelli University Polyclinic Foundation IRCCS, or Policlinico Gemelli, one of Italy’s largest and most renowned hospitals known for its advanced oncology services, including diagnostics, treatment, and research, to establish an in-house liquid biopsy testing service within its hospital system. system, and in December 2025, the liquid biopsy testing service based on our proprietary Guardant360® CDx technology became available at the Policlinico Gemelli facility in Italy.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
Cost of development services and other primarily revenue also includes costs incurred for the performance of development services requested by our biopharmaceutical customers, service agreements and costs associated with our partnership agreements with biopharmaceutical customers and delivery of Shield screening tests, strategic partners, which comprise of labor and material costs including any inventory write-downs. costs.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
We have also launched offer the Guardant360 TissueNext tissue Tissue test for advanced-stage cancer, cancer and the Guardant Reveal blood test to detect residual and recurring disease in early-stage colorectal, breast and lung cancer patients, and Guardant360 Response blood test to predict patient response to immunotherapy or targeted therapy eight weeks earlier than current standard-of-care imaging. patients.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
Cash used in investing activities during the year ended December 31, 2024 2025 was $261.3 $627.2 million, which resulted primarily from purchases of marketable debt securities of $307.3 $818.2 million, business acquisition net of cash acquired of $59.0 million, purchases of property and equipment of $35.1 $48.3 million, and purchases of non-marketable equity security investments of $7.5 $9.0 million; partially offset by sales of marketable equity security investment in Lunit, Inc. of $53.6 million and maturities of marketable debt securities of $35.0 $307.3 million.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
As we continue to develop these relationships, we expect to support a growing number of clinical studies globally and continue to have opportunities to offer our platform services to such customers for development services, customers, primarily including companion diagnostic development, novel target discovery development and validation, as well as clinical study enrollment. regulatory approval, monitoring and maintenance, GuardantINFORM data services and GuardantConnect referral services.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
Total Oncology revenue was $739.0 $683.6 million for the year ended December 31, 2025, compared to $542.8 million for the year ended December 31, 2024, compared to $563.9 million for the year ended December 31, 2023, an increase of $175.1 $140.8 million, or 31%. 26%.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new